Category : Gut Microbiota

Dr Tom van den Bogert focused his research on small intestinal microbiota combining cutting edge omics method like metagenomics. He accepted to give us more detailed information about his work conducted in TIFN framework. We advise our readers to follow him on twitter @TomvandenBogert. What is your background? My studies started in Rotterdam where I obtained a bachelor's degree with a specialization in…

GMFH Editing Team
GMFH Editing Team

Dr Tom van den Bogert focused his research on small intestinal microbiota combining cutting edge omics method like metagenomics. He accepted to give us more detailed information about his work conducted in TIFN framework. We advise our readers to follow him on twitter @TomvandenBogert. What is your background? My studies started in Rotterdam where I obtained a bachelor's degree with a specialization in…

GMFH Editing Team
GMFH Editing Team

Research Director at INRA, Joël is Scientific Director of MetaGenoPolis (www.mgps.eu). He is the leader of the team ‘functionalities of the intestinal ecosystem’ within the Micalis Institute “Food and Gut Microbiology for Human Health” (http://www.micalis.fr/micalis_eng/Poles-and-teams/Pole-Ecosystems/FInE-Dore) and scientific board member of Microbiology Pole of the Doctoral School “Therapeutic Innovations” at Paris-XI University. Joel joined INRA in 1983 and received his PhD…

GMFH Editing Team
GMFH Editing Team

Research Director at INRA, Joël is Scientific Director of MetaGenoPolis (www.mgps.eu). He is the leader of the team ‘functionalities of the intestinal ecosystem’ within the Micalis Institute “Food and Gut Microbiology for Human Health” (http://www.micalis.fr/micalis_eng/Poles-and-teams/Pole-Ecosystems/FInE-Dore) and scientific board member of Microbiology Pole of the Doctoral School “Therapeutic Innovations” at Paris-XI University. Joel joined INRA in 1983 and received his PhD…

GMFH Editing Team
GMFH Editing Team

Prof. Jeffrey Gordon was invited to give a TED talk at the TEDxGatewayArch. His talk introduces the ideas of microbiota and microbiome, a new view to our connection to the microbial world as humans. He goes on detailing how our microbiome is for us a new way of considering our human evolution: it's a part of evolution that goes much…

GMFH Editing Team
GMFH Editing Team

Prof. Jeffrey Gordon was invited to give a TED talk at the TEDxGatewayArch. His talk introduces the ideas of microbiota and microbiome, a new view to our connection to the microbial world as humans. He goes on detailing how our microbiome is for us a new way of considering our human evolution: it's a part of evolution that goes much…

GMFH Editing Team
GMFH Editing Team

Dr Elena Verdú's lab seeks to understand the complex pathophysiology of gastrointestinal disease, with a focus on microbiota-diet interactions, to identify novel therapeutic targets for these disorders.     1/ What strikes you most in the evolution of research on gut microbiota and why? One interesting aspect relates to the way we have approached the study of the microbiota. We…

GMFH Editing Team
GMFH Editing Team

Dr Elena Verdú's lab seeks to understand the complex pathophysiology of gastrointestinal disease, with a focus on microbiota-diet interactions, to identify novel therapeutic targets for these disorders.     1/ What strikes you most in the evolution of research on gut microbiota and why? One interesting aspect relates to the way we have approached the study of the microbiota. We…

GMFH Editing Team
GMFH Editing Team

Professor Barbara’s main scientific interest is in functional gastrointestinal disorders, including constipation, irritable bowel syndrome and diarrhea. These conditions have been considered for a long time mood disorders. However, there is clear recognition that peripheral and environmental factors as well as the intestinal microbiota participate to their pathophysiology. Subsets of patients develop these condition after a bout of infectious gastroenteritis,…

GMFH Editing Team
GMFH Editing Team

Professor Barbara’s main scientific interest is in functional gastrointestinal disorders, including constipation, irritable bowel syndrome and diarrhea. These conditions have been considered for a long time mood disorders. However, there is clear recognition that peripheral and environmental factors as well as the intestinal microbiota participate to their pathophysiology. Subsets of patients develop these condition after a bout of infectious gastroenteritis,…

GMFH Editing Team
GMFH Editing Team

Gnotobiotic animals have long been used to highlight major functions of the intestinal microbiota such as its contribution to trophic development of gut tissues, immune maturation, direct protection from colonization/proliferation of pathogens (the barrier effect) and more recently its implication in metabolism and fat storage. Yet gnotobiology had never been used in a systematic way as a screening tool. This…

Fernando Aspiroz

Gnotobiotic animals have long been used to highlight major functions of the intestinal microbiota such as its contribution to trophic development of gut tissues, immune maturation, direct protection from colonization/proliferation of pathogens (the barrier effect) and more recently its implication in metabolism and fat storage. Yet gnotobiology had never been used in a systematic way as a screening tool. This…

Fernando Aspiroz

Catherine Juste studied agronomic engineering, and then became Doctor of Science, specializing in nutrition and physiology. She became passionate about environmental microbiology and is currently developing environmental proteomics of the gut microbes at INRA. She developed an innovative preparative pipeline to explore myriads of bacterial proteins that are expressed in the lumen gut of human hosts, and that may have…

GMFH Editing Team
GMFH Editing Team

Catherine Juste studied agronomic engineering, and then became Doctor of Science, specializing in nutrition and physiology. She became passionate about environmental microbiology and is currently developing environmental proteomics of the gut microbes at INRA. She developed an innovative preparative pipeline to explore myriads of bacterial proteins that are expressed in the lumen gut of human hosts, and that may have…

GMFH Editing Team
GMFH Editing Team

In this video Dr. Jeffrey Bland discusses recent research into the gut microbiome. Some of the research cited includes work done by the Cleveland Clinic showing certain gut microbiota may convert animal products consumed in the diet into secondary metabolites that are possibly heart-disease inducing (“the Bad”). However, research out of Europe appears to demonstrate particular gut flora may enhance…

GMFH Editing Team
GMFH Editing Team

In this video Dr. Jeffrey Bland discusses recent research into the gut microbiome. Some of the research cited includes work done by the Cleveland Clinic showing certain gut microbiota may convert animal products consumed in the diet into secondary metabolites that are possibly heart-disease inducing (“the Bad”). However, research out of Europe appears to demonstrate particular gut flora may enhance…

GMFH Editing Team
GMFH Editing Team

Faecal microbiota transplantation (FMT) has emerged as an effective treatment for Clostridium difficile infections that were stubborn to antibiotic therapy. However, other clinical indications of FMT are receiving an increasing attention due to the relevant roles of the microbiota in the function of the gastrointestinal tract and other aspects of human physiology. In consequence, studies of FMT for recurrent Clostridium…

GMFH Editing Team
GMFH Editing Team

Faecal microbiota transplantation (FMT) has emerged as an effective treatment for Clostridium difficile infections that were stubborn to antibiotic therapy. However, other clinical indications of FMT are receiving an increasing attention due to the relevant roles of the microbiota in the function of the gastrointestinal tract and other aspects of human physiology. In consequence, studies of FMT for recurrent Clostridium…

GMFH Editing Team
GMFH Editing Team

Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.

Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.